Immunogenetics pp 359-377 | Cite as

Crossmatching by Complement-Dependent Lymphocytotoxicity

  • Samantha J. Fidler
Part of the Methods in Molecular Biology book series (MIMB, volume 882)


The presence of preformed donor-specific HLA antibodies detected by Complement-dependent cyto­toxicity (CDC) crossmatch assay is associated with a high incidence of hyperacute or accelerated rejection and remains one of the gold standard tests pre-transplant. The standard CDC crossmatch detects IgG1, IgG3, and IgM antibody, i.e. complement fixing, bound to the native viable cell surface of lymphocytes. The crossmatch can be enhanced with the addition of anti-human-globulin to detect non-complement fixing antibodies (IgG2 and IgG4), and sensitivity can be improved with prolonged incubation times.

Key words

Crossmatch Complement-dependent cytotoxicity Alloantibody Autoantibody IgG IgM 


  1. 1.
    Patel R, Terasaki PI (1969) Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280:735–739PubMedCrossRefGoogle Scholar
  2. 2.
    Nickerson P, Pochinco D, Karpinski M et al (2004) Class II donor specific antibodies are pathogenic in primary renal allografts. Am J Transplant 4:257CrossRefGoogle Scholar
  3. 3.
    Eng HS, Bennett G, Humphreys I et al (2008) Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 8:2335–2342PubMedCrossRefGoogle Scholar
  4. 4.
    Gebel HM, Bray RA, Nickerson P (2003) Pre-transplant assessment of donor-reactive. HLA specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 3:1488–1500PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Clinical Immunology, PathWest Laboratory MedicineRoyal Perth HospitalPerthAustralia
  2. 2.School of Pathology and Laboratory Medicine (PaLM)University of Western AustraliaNedlandsAustralia

Personalised recommendations